Overview

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advance

Status:
Recruiting

Trial end date:
2022-08-31

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to identify the recommended Phase 2 dose (RP2D) of JNJ-63723283 as a monotherapy (Phase 1a part) and to identify the RP2D of JNJ-63723283 when administered in combination with Erdafitinib (Phase 1b part).

Phase:

Phase 1

Details

Lead Sponsor:

Janssen Pharmaceutical K.K.

Treatments:

Antibodies
Antibodies, Monoclonal